Theragnostics Opens U.S. Headquarters in Boston, Massachusetts
08/24/2017
Under the agreement, Theragnostics will distribute select ROTOP products in the U.S., Canada, Australia and New Zealand. In addition, ROTOP will manufacture GalliProst, Theragnostics' lead imaging candidate, and other agents in development, with distribution rights in the European Union and Switzerland.
Theragnostics' new headquarters is located in the historic Charlestown section of Boston, with close access to the region's prestigious teaching hospitals and global biotechnology hub. Products are expected to be available in the U.S. beginning September 1, 2017.
"Our relationship with ROTOP reflects our mission to serve the nuclear medicine community by delivering precisely targeted imaging and therapy agents for cancer patients and others," said Patrick Donahue, CEO, Theragnostics, Inc.
"It also supports our strategy to build revenue alongside the clinical development of our proprietary Galli® platform, which we believe will expand the power of PET imaging for thousands of physicians,” he added.
Project Announcements
Ferrero Expands Brantford, Ontario, Canada, Production Operations
04/19/2025
Switzerland-Based ABB Expands Senatobia, Mississippi, Production Operations
04/19/2025
Wow Bao Plans Forest City, North Carolina, Manufacturing Operations
04/19/2025
B-K Tool & Design Expands Putnam County, Ohio, Manufacturing Operations
04/19/2025
Lucid Group Plans Phoenix-Coolidge, Arizona, Manufacturing Operations
04/19/2025
Coast Expands Expands Salt Lake County, Utah, Operations
04/15/2025
Most Read
-
Run a Job Task Analysis
Q4 2024
-
The Location Economics of Advanced Nuclear
Q1 2025
-
39th Annual Corporate & 21st Annual Consultants Surveys: What Business Leaders and Consultants Are Saying About Site Selection
Q1 2025
-
NEW NIMBYism: A Threat to The U.S. Economy
Q4 2024
-
Power, Policy, and Site Selection in 2025
Q1 2025
-
Designing Beyond the Assembly Line
Q1 2025
-
Why Workforce Readiness Can’t Wait
Q1 2025